Business Context and Reporting Period
Prestige Brands Holdings, Inc. (now Prestige Consumer Healthcare Inc.) filed this Form 8-K on September 18, 2006, to disclose the entry into a Material Definitive Agreement. The filing concerns a strategic supply arrangement for Clear Eyes and Murine eye care products.
Key Financial Metrics
This filing is a current report regarding a contractual agreement and does not contain financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Agreement Details
- Agreement Parties: Prestige Brands Holdings, Inc. (via subsidiary Medtech Products Inc.) and Aspen Pharmacare Holdings Limited (via subsidiary Pharmacare Limited).
- Product Scope: Exclusive supply of Clear Eyes and Murine eye care products for the U.S. and Canada markets.
- Timeline: The exclusive supply term commences January 1, 2009, and terminates December 31, 2013.
- Transition Period: Prior to 2009, Medtech may purchase from Aspen, Abbott Laboratories, or other third parties. Abbott will supply excess demand until its facility closes on December 31, 2007.
- Cost Structure: Product costs (including delivery to the U.S.) are stated to be substantially similar to current costs paid to Abbott.
- Infrastructure: Aspen/Pharmacare agreed to construct a new manufacturing facility to meet Medtech's requirements, with completion targeted for January 1, 2009.
Outlook, Risks, and Management Commentary
Management entered this agreement because Abbott Laboratories notified the Registrant it would not continue supplying the products after December 31, 2007. Aspen/Pharmacare was selected for its status as a world-class multinational manufacturer with existing agreements with major pharmaceutical companies. The filing notes that both the Registrant and Holdings have guaranteed the payment and performance obligations of their respective subsidiaries under the agreement. A key contingency is the timely completion of the new facility and regulatory compliance to ensure supply continuity starting in 2009.
Investor Verification Checklist
- Verify the construction timeline and regulatory approval status of the new Aspen/Pharmacare manufacturing facility.
- Confirm the specific terms of the transition period between Abbott's exit (end of 2007) and Aspen's exclusive supply start (2009).
- Review the financial impact of the supply agreement on future cost of goods sold, despite the claim of cost similarity.
- Assess the creditworthiness and operational capacity of Aspen/Pharmacare as a sole supplier for the 2009-2013 period.